NCT07793396 Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
| NCT ID | NCT07793396 |
| Status | Recruiting |
| Phase | — |
| Sponsor | King Edward Medical University |
| Condition | Focal-Onset Seizures |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-12-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-12-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.
Eligibility Criteria
Inclusion Criteria: * Adult patients (aged at least 18 years) with diagnosed partial-onset seizures. * Newly diagnosed (treatment-naïve) or previously treated with Carbamazepine or Oxcarbazepine and inadequately controlled or intolerant. * Patient or Legal Representative is willing and able to provide informed consent, or, in the absence of a legal representative, an Independent Healthcare Professional provides authorization for patient enrolment. Exclusion Criteria: * Any hypersensitivity to Eslicarbazepine. * Female patients who are pregnant or lactating. * Patients who have a contraindication to the medicine or any component of prescribed therapy.
Contact & Investigator
Safia Assistant Professor Neurology, FCPS Neurology, PhD Scholar
✉ safiabano@kemu.edu.pk📞 +92-301-4154276
Frequently Asked Questions
Who can join the NCT07793396 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Focal-Onset Seizures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07793396 currently recruiting?
Yes, NCT07793396 is actively recruiting participants. Contact the research team at safiabano@kemu.edu.pk for enrollment information.
Where is the NCT07793396 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07793396 clinical trial?
NCT07793396 is sponsored by King Edward Medical University. The trial plans to enroll 1,500 participants.